Details

Autor(en) / Beteiligte

• Deeks, Steven G.
• Archin, Nancie
• Cannon, Paula
• Collins, Simon
• Jones, R. Brad
• de Jong, Marein A. W. P.
• Lambotte, Olivier
• Lamplough, Rosanne
• Ndung’u, Thumbi
• Sugarman, Jeremy
• Tiemessen, Caroline T.
• Vandekerckhove, Linos
• Lewin, Sharon R.

Titel

Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021

Ist Teil von

• Nature medicine, 2021-12, Vol.27 (12), p.2085-2098

Ort / Verlag

New York: Nature Publishing Group US

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong treatment is required and there is no cure. HIV can integrate in the host genome and persist for the life span of the infected cell. These latently infected cells are not recognized as foreign because they are largely transcriptionally silent, but contain replication-competent virus that drives resurgence of the infection once ART is stopped. With a combination of immune activators, neutralizing antibodies, and therapeutic vaccines, some nonhuman primate models have been cured, providing optimism for these approaches now being evaluated in human clinical trials. In vivo delivery of gene-editing tools to either target the virus, boost immunity or protect cells from infection, also holds promise for future HIV cure strategies. In this Review, we discuss advances related to HIV cure in the last 5 years, highlight remaining knowledge gaps and identify priority areas for research for the next 5 years. An effective and scalable cure strategy is a top priority for the HIV research field; this Review discusses recent advances, knowledge gaps, and priority research areas for the next 5 years.